Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?

Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.

31.03.2026 4

Quartz

Kanishka das